Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine prophylaxis for poor graft function and prolonged thrombocytopenia after haploidentical HSCT
IRCT20140818018842N19Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoints: Cumulative incidence of poor graft function and prolonged isolated thrombocytopenia, Cumulative incidence of acute graft-versus-host disease and 4 more. Started Aug 2020; status: completed.
02
Drugs
acetylcysteine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on IRCT20140818018842N19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N19.